Process Analytical Technologies for Pharmaceuticals Market - Global Industry Analysis, Trends and Forecast 2016 - 2023

Pharmaceutical product manufacturing comprises stringent procedure in which monitoring and regulation of each and every step is highly essential and crucial affair. The pharmaceutical products are related with the health and life of an individual; hence the errorless analysis of each and every step is required.

According to the U.S. FDA, process analysis technology (PAT) can be defined as a mechanism or system used to analyze, evaluate and control pharmaceutical manufacturing process with the help of evaluation of critical process parameters (CPP) that influences critical quality attributes (CQA). Owing to tight regulations and requirements of various international certificates such as ISO and GMP for critical monitoring of pharmaceutical processes, the demand of these techniques has been increased.

Request For Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=9028

The market of process analytical technologies for pharmaceuticals can be segmented on the basis of processes (services), equipment and applications of PAT. The equipment are further divided into spectrophotometers (mass spectrometer, UV-Visible spectrophotometer, nuclear magnetic resonance spectrophotometer, infrared spectrometers), chromatography instrument set (thin layer chromatography, gas chromatography, liquid chromatography), dissolution instrument, particle size analyzers (sieving, sedimentation, dynamic light scattering, aerosol mass spectrometry), capillary electrophoresis devices and others (hardness tester, physical properties [size, shape, color], friability test). On the basis of services, it is segmented into consultancy, calibration and database management system (DBMS). Moreover, on the basis of applications, it is divided into lyophilization, coating, compression, evaporation, raw material selection, packaging and others. Additionally, the market is segmented on the basis of geography, such as North America, Europe, Asia-Pacific and Rest of the World (RoW). At present, North America and Europe are the most prominent markets, owing to extensive pharmaceutical industries. However, Asia-Pacific and some countries in RoW are expected to show lucrative growth in the upcoming period, owing to increase in number of pharmaceutical infrastructure and technologies.

The market of process analytical technologies for pharmaceuticals is expected to show a lucrative growth during the forecast period from 2014 to 2020. This growth is expected to fuel by the factors such as strong pharmaceutical infrastructure in developed countries and rapid increase in number of pharmaceutical production units in the developing countries and technological advancements. Increasing pharmaceutical production and R&D are considered as the most important drivers of this market. For instance, according to the statistics provided by the European Federation of Pharmaceutical Industries and Association (EFPIA), the pharmaceutical production in Europe has increased from USD 112,000 million in 1990 to USD 2,620,000 million in 2012. This astonishing increase in pharmaceutical sector is expected to propel the market growth during the forecast period from 2014 to 2020. Furthermore, owing to technological advancements, a number of new and technologically sound devices are entering in the global market and the entry of these devices is anticipated to contribute in the growth of the market. Other important factors that are likely to drive market growth include increasing regulatory and government pressure to implement various tests during manufacture, rising prevalence of different diseases that fuels the demand of pharmaceutical formulations and others. On the other hand, high cost and tedious operations of the instruments, lack of technically competent workforce and threat of malfunctions and false results are the key hurdles that are likely to limit the growth of PAT market during the forecast period from 2014 to 2020.

Some of the major companies operating in this market include Danaher Corporation, Honeywell, Agilent Technologies, Fluke Biomedical, Tektronix, Inc. Thermo Fisher Scientific, Inc. and Carl Zeiss AG amongst others.

Gynecological Devices Market Segment Forecast up to 2023

According to a new market report published by Transparency Market Research “Gynecological Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023”, global gynecological devices market was valued at US$14.9 bn in 2014 and is projected to reach US$22.6 bn in 2023 at a CAGR of 4.8% from 2015 to 2023.

The continued growth in the global gynecological devices market is attributed to the changing lifestyle in the modern world, and increase in per capita income in the emerging markets. Prevalence of gynecological diseases such as menorrhagia, uterine fibroids, and cervical cancers has increased globally. The report on global gynecological devices market has been segmented on the basis of product type and geography. The products include surgical devices, hand instruments, diagnostic imaging systems, and gynecological chairs market. The gynecological surgery devices include fluid management systems, female sterilization and contraceptive devices, endoscopy devices, and endometrial ablation devices.

Request A Sample Of This Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=613

Amongst the major product segments, diagnostic imaging systems is expected to growth at a CAGR of 5.8% during the forecast period from 2015 to 2023. Technological innovation such as incorporation of efficient lighting in diagnostic systems and growth in preference for early detection and prevention of gynecological diseases are the major drivers of this segment. Surgical devices accounted for the largest share in the global gynecological devices market due to sheer number of devices and the uniqueness in their applications. Presently, the female sterilization and contraceptive devices dominate the market in terms of revenue, and its market share will continue to remain largest in the 2023. Fluid management systems are expected to witness highest growth among the surgical device segment.

Geographically, this report covers the global gynecological devices market into North America, Europe, Asia Pacific, Latin America, and Rest of the World (RoW). In 2014, North America held the largest share of the global gynecological devices market and will continue to dominate the global gynecological devices market. However, the presence of large patient pool, rising preference for minimally invasive procedures, and improving macroeconomic environment in Asia Pacific offers a promising market for gynecological devices in the near future.

Some of the key companies profiled in this report include Boston Scientific Corporation, Hologic, Inc., CooperSurgical, Inc., Ethicon, Inc., Karl Storz GmbH, Medtronic, Inc., Olympus Corporation, Richard Wolf GmbH, and Stryker Corporation.

Global Gynecological Devices Market is segmented as below:

Global Gynecological Devices Market, by Product Types

• Surgical devices
  • Gynecological endoscopes
    • Hysteroscopes
    • Colposcopes
    • Resectoscopes
    • Laparoscopes
  • Endoscopic imaging systems
    • Endometrial ablation devices
    • Hydrothermal endometrial ablation devices
    • Radiofrequency endometrial ablation devices
    • Balloon endometrial ablation devices
    • Other endometrial ablation devices (cryoablation, microwave ablation, laser ablation)
  • Gynecologic fluid management systems
  • Female sterilization and contraceptive devices
    • Permanent birth control devices
    • Temporary birth control devices
  • Hand instruments
    • Vaginal Speculum
      • Disposable
      • Reusable
    • Tenaculum
    • Curettes
    • Trocars
    • Biopsy forceps
    • Others
  • Diagnostic imaging systems
    • Ultrasound
    • Mammography
  • Gynecological chairs
    • Fixed-height gynecological chairs
    • Adjustable-height gynecological chairs

Global Gynecological Devices Market, by Geography

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Rest of the World

Contact us:

Mr. Sudip S

Transparency Market Research

90 State Street,

Suite 700,

Albany

NY - 12207

United States

Tel: +1-518-618-1030

USA - Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

Rabies Treatment Market Trends and Forecast 2016 - 2023

Rabies is a zoonotic viral disease caused due to animal bits. The disease is known to affect domestic as well as wild animals such as bats, skunks, foxes, ferrets, raccoons, cats, or dogs, and infects humans upon contact with saliva of infected animal. Rabies is known to have an incubation period of one to three months. Individuals suffering from rabies show initial symptoms of fever and pain or tingling or burning sensation also called as paraesthesia at the wound site. As the disease progresses through the central nervous system (CNS), patients exhibit hyperactivity, excited behavior, hydrophobia. Rabies can also be paralytic and accounts for approximately 3% of all rabies cases globally according to World Health Organization (WHO). This form is usually misdiagnosed and has slower progression. Muscles near the wound site begin to paralyze; untreated infections lead to coma and cause death.

WHO statistics also show that although rabies is prevalent in all continents except Antarctica, more than 95% of the mortalities occur in African and Asian countries. Rabies infections are common in areas where human-animal interaction is more and no proper medical treatment facility is available for treatment. In the U.S. only 55 cases have been identified since 1955 according to Centers for Disease Control and Prevention (CDC). Rapid diagnostic tests are available for diagnosis of rabies. These tests are usually Enzyme Linked Immunosorbent Assay (ELISA) or fluorescent assay technology. Synbiotics Corporation, O.K. SERVIS BioPro, s.r.o., Bio-Rad Laboratories, Inc. and Alpha Diagnostic International are some of the players manufacturing diagnostic kits for rabies.

Get Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=9022

Novartis and Sanofi are key players in the global rabies treatment market. These companies manufacture prophylactic vaccines for humans. Sanofi’s Imovax Rabies is a human diploid cell vaccine; while Novartis’s RabAvert is a Purified chick embryo cell vaccine. Vaccines are also available for preventing infections in animals. Merial a Sanofi company announced in July 2014 had it has launched PUREVAX Feline Rabies 3 YR vaccine. This is a non-adjuvanted rabies vaccine and provides 3 year immunity. The vaccine has been recommended for immunization of healthy cats 12 weeks and older. Cadila Pharmaceuticals Ltd, is also working on development of new generation rabies vaccine in India. Under-developed countries have initiated mass vaccination of stray dogs to control mortalities. According to an article published by World Health Organization (WHO) in 2014, Kenya launched a nationwide program for vaccination of dogs. Currently, more than 3,000 dogs in Makueni County have been vaccinated. In September 2014, The Philippines Department of Agriculture (DA), the Australian Government and the World Organization for Animal Health (OIE) launched rabies control project to reduce rabies cases due to dog in the Philippines. Earlier in 2013, massive dog vaccination program was launched, which vaccinated 92,869 dogs and attained 80% coverage according to a press release by World Organization for Animal Health. An article published in The Maravi Post, Malawi also plans to vaccinate 500,000 dogs and cats to curb the rabies crisis. Such preventive programs will help in reducing the prevalence of the disease in lower socio-economic classes. With developing economic conditions and consistent government initiatives, the prevalence of rabies is expected to shrink in the future. Higher prevalence in the Asia Pacific and Africa provides larger customer base for players in the rabies treatment market.

Testicular Cancer Drugs Market Offering High-growth Opportunities for Market Players

Testicular cancer is observed in males aged between 15 to 44 years where major symptoms include forming a painless lump or swelling in testicles. If the cancer is left untreated, the eventual course is metastasis and mortality. However, due to advances in multimodal treatments which include surgery, radiation and chemotherapy, a cure for this type of cancer is commonly achieved. Testicular cancer is classified into different types of cancer depending on the type cell in which cancer begins. Cancer developed in germ cells is termed as germ cell testicular cancer and is the most common type. Germ cell testicular cancers account for more than 95% of all testicular cancer cases and are further segmented into seminomas and non-seminomas which approximately account for 40% and 60% of total germ cell testicular cancer. The other less prevalent types of testicular cancers include include Leydig cell tumors (1% to 3%) and Sertoli cell tumors (less than 1%). The treatment of testicular cancer is determined on the type of cancer and the level of advancement of tumor within the body.

Request For Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8206

Testicular cancer itself is a relatively uncommon and accounts for less than 1 percent of all types of cancer incidences. Globally the cancer is more prevalent in the developed regions which include Australia, North America and Europe. In 2011, approximately 2,207 men in the U.K. were diagnosed with testicular cancer while 68 men died from this disease. The American Cancer Society estimates that in 2014 about 8,820 new cases of testicular cancer will be diagnosed and 380 deaths will occur in the U.S. The rate of incidences of testicular cancer has been observed to be rising every year across the world, however the curability of this disease has increased the survival rate of patients affecting with it. For instance, only four percent of testicular cancer patients in the U.S. die within first five years of getting the disease. Hence, more people are getting treated each year with this type of cancer which reflects the growth of the global testicular cancer drugs market.

The global testicular cancer drugs market is classified on the basis of cancer types into three segments, namely germ cell cancer drugs market, Leydig cell cancer drugs market and Sertoli cell cancers market. The main drugs used in treating testicular cancer are cisplatin, etoposide, ifosfamide, paclitaxel, and vinblastine. Other drugs used for treating testicular cancer include bleomycin, dactinomycin. The treatment is more effective if the chemotherapy regimen involve 2 or more drugs rather than using any single drug. The common chemotherapy regimens for treatment of testicular cancer are BEP (bleomycin, etoposide, and cisplatin), EP (etoposide and cisplatin), TIP (paclitaxel, ifosfamide, and cisplatin), and VIP (VP-16/etoposide or vinblastin, ifosfamide and cisplatin). Some of these drugs can have serious side effects such as kidney damage, lung damage, neuropathy, and hemorrhagic cystitis and therefore have to be administered with utmost care and monitoring the effects of these drugs. However, the side effects last shortly and do not affect the patient permanently unless the dosage regimens include very high doses for ling duration.

Some of the key players in the global testicular cancer drugs market include Bristol-Myers Squibb Co., Hospira Inc., Ovation Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., ZIOPHARM Oncology Inc., Fresenius Kabi AG and Teva Parenteral Medicines, Inc.

Healthcare Mobility Solutions To Make Great Impact In Near Future by 2023

The advancements in assistive technologies have enabled many over the years to lead a normal life free from dependency. Personal mobility devices have been designed to help the user enhance their mobility experience that may be impaired due to a range of health conditions such as arthritis, cerebral palsy, spina bifida, muscular dystrophy, poliomyelitis, spinal cord injuries, stroke, and visual impairment.

Reducing Cost of Assistive Technologies with Insurance Boosts Market for Mobility Devices

In recent years, the global personal mobility devices market has witnessed a sudden surge due to the entry of health insurance players and a growing geriatric population. The two complement each other, as the growing pool of senior citizens that require assistive devices can now easily afford these devices, as insurance companies are helping in bringing down the costs of the same. Furthermore, the growing number of organizations and institutions working towards providing assistance to the disabled is also boosting the global personal mobility devices market. These factors put together are expected to propel the growth of the global personal mobility devices market.

The global personal mobility devices market is segmented into medical mobility aids and ambulatory devices and medical furniture and bathroom safety products. The medical mobility aids and ambulatory devices segment has been further sub-segmented into scooters, wheelchairs, canes and crutches, walkers, stair lifts, and others. On the other hand, the medical furniture and bathroom safety products segment is sub-divided into medical beds, bars and railings, patient lifts, commodes and shower chains, and others. Geographically, the global personal mobility devices market is segmented into North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa.

Get Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=6715

Wheelchairs and Medical Beds the Most Popular Products in Global Personal Mobility Devices Market

In terms of products, wheelchairs and medical beds will show the fastest growth rate in the global personal mobility devices market in the coming years. The prime growth drivers for these product segments are the growing prevalence of chronic diseases, the longevity and durability of wheelchairs and medical beds, growing expenditure by governments, and a high rate of disabilities.

Out of all the geographical segments of the global personal mobility devices market, North America held the largest share of 41.4% in 2014. This commendable share was a result of the well-established healthcare infrastructure, rise in the number of the geriatrics and the disabled, supportive government regulations, and a growing demand for new and innovative products that are being launched in the market.

Asia Pacific Offers Lucrative Opportunities to Personal Mobility Devices Market

Asia Pacific is also expected to show a good growth rate all the way till 2023. The boost for the personal mobility devices market in Asia Pacific will be largely due to the improving disabled-friendly public infrastructure and strengthening economies of Singapore, South Korea, and Japan. The market in Asia Pacific will also be propelled by the reduction in manufacturing costs, complemented by the growing demand for innovative mobility devices. This trend has also encouraged several manufacturing companies to take over the reins in the market.

Some of the key players in the global personal mobility devices market are Amigo Mobility International, Inc., ArjoHuntleigh, Drive Medical, Graham-Field Health Products Incorporated, Argo Medical, Hill-Rom Holdings, Inc., Stryker Corporation, Otto Bock Healthcare GmbH, Invacare Corporation, Permobil AB, Pride Mobility Products Corporation, Patterson Medical Holdings, Inc., and Sunrise Medical LLC.

Digital and Portable Imaging Equipment to Lead Global Medical Imaging Equipment Market

According to a recent market research report published by Transparency Market Research, the global medical imaging equipment market is projected to expand at a CAGR of 5.6% during the period between 2015 and 2023. The report, titled “Medical Imaging Equipment Market - Global Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast, 2015 - 2023”, estimates the global medical imaging equipment market to reach a valuation of US$45.3 bn by 2023. The overall market was worth US$27.7 bn in 2014.

The report points out that the growing prevalence of target diseases and rapidly increasing geriatric population will fuel the demand for medical imaging equipment. Rise in demand for 3D medical imaging equipment, coupled with initiative taken by government and private organizations, will further propel the growth of the global medical imaging equipment market. However, the increasing pressure on healthcare budgets in the U.S. and excise duty imposed on medical device manufacturers will play spoilsport in the growth of the market during the forecast horizon. Low adoption of digital technology-based systems, conventional CT, and MRI scanners among patients will also negatively impact the market. The global medical imaging equipment market has a huge opportunity to grow with the introduction of cloud-based medical imaging.

In terms of product types, the report segments the global medical imaging equipment market into ultrasound systems, X-ray devices, computer tomography (CT) scanners, magnetic resonance imaging (MRI) equipment, and nuclear imaging equipment. X-ray imaging devices dominated the overall market in 2014. The growing prevalence of cardiovascular, respiratory, and gastrointestinal disorders and easy availability of X-ray devices have driven the demand for X-ray imaging devices. Stationary X-ray devices are more in demand compared to portable X-ray equipment devices due to their low cost.

Brochure Download: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=105

The demand for ultrasound systems is expected to surge during the forecast horizon owing to high adoption rates across the globe. Cost-effectiveness, safety, and real-time image formation are some of the benefits of ultrasound imaging over CT and MRI scans. Earlier, the applications of ultrasound systems were restricted to abdominal imaging. However, they are now extensively used to image the kidneys, heart, and other organs. In ultrasound imaging, the commonly used technologies are 2-D, 3-D, and 4-D imaging, lithotripsy, Doppler, and high intensity focused ultrasound (HIFU). Nuclear imaging devices have emerged as a recent development in the global medical imaging equipment market and are expected to witness wide adoption by the end of the forecast horizon.

Describing competitive landscape, the report profiles some of the key players in the global medical imaging equipment market such as GE Healthcare, Hitachi Medical Corporation, Philips Healthcare, Siemens Healthcare, Shimadzu Corporation, Hologic Inc, Samsung Medison Co. Ltd., Carestream Health Inc., Genesis Medical Imaging Inc., Fonar Corporation, Toshiba Corporation, and Fujifilm Holdings Corporation. The global medical imaging equipment market has witnessed the dominance of a few leading players such as GE Healthcare, Philips Healthcare, Toshiba Corporation, and Siemens Healthcare.

The global medical imaging equipment market is segmented into the following categories:

Medical Imaging Equipment Market, by Product

• X-Ray Devices
  • Stationary
  • Portable
• Ultrasound Systems
  • Cart/Trolley Based Ultrasound System
  • Compact/Portable Ultrasound System
• Computed Tomography (CT) Scanners
  • Stationary
  • Mobile
• Magnetic Resonance Imaging (MRI) Equipment
  • Closed
  • Open
• Nuclear Imaging Equipment
  • SPECT Scanner
  • PET Scanner

Medical Imaging Equipment Market, by Technology

• X-Ray Devices
  • Analog X-ray Technology
  • Digital Radiography
  • Computed Radiography
• Ultrasound Systems
  • 2-D
  • 3-D & 4-D
  • Doppler
  • High Intensity Frequency Ultrasound (HIFU)
  • Lithotripsy
• Computed Tomography (CT) Scanners
  • Stationary
  • Mobile
• Magnetic Resonance Imaging (MRI) Equipment
  • Low-Slice
  • Medium-Slice
  • High-Slice
• Nuclear Imaging Equipment
  • SPECT Scanner
  • PET Scanner

Medical Imaging Equipment Market, by Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa (MEA)

Contact us:

Mr. Sudip S

Transparency Market Research

90 State Street,

Suite 700,

Albany

NY - 12207

United States

Tel: +1-518-618-1030

USA - Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

Global Clinical Laboratory Services Market Fueled by Growing Prevalence of Chronic and Debilitating Medical Conditions

Clinical laboratories provide various tests that aid in detecting abnormalities and the progression of diseases. Clinical diagnostic tests are performed widely by laboratories globally. These clinical diagnostic tests range from routine urine and blood tests to high-end genetic analysis. Molecular expression testing and fluorescence in situ hybridization are examples of diagnostic tests.

According to a study by Transparency Market Research, a global market intelligence firm, in 2012, the global clinical laboratory services market was valued at US$162.7 bn and is estimated to reach a value of US$241.3 bn by the end of 2019. This market is expected to exhibit a 5.80% CAGR between 2013 and 2019.

The global market for clinical laboratory services offers several types of tests such as human and tumor genetics, clinical chemistry, medical microbiology and cytology, and other esoteric tests. The three major service providers in the clinical laboratory services market are stand-alone, clinic-based, and hospital-based. Among these types, the hospital-based laboratories segment is expected to lead the global market owing to the vast difference in testing volumes of these laboratories when compared to the other two service providers. Nevertheless, stand-alone laboratories are gaining importance due to the quick processing of samples and easy access for patients.

Request for Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=414

Some of the major factors that are expected to fuel the growth of the global clinical laboratory services market are:

• The growing prevalence of diseases such as diabetes, cancer, and other infectious diseases are forcing patients to opt for several tests

• The detection of diseases at an early stage with the help of specialized diagnostic tests is boosting the demand for several other clinical laboratory services

• The geriatric population in the U.S. is expected to grow by 20% by the end of 2030, leading to a high demand for clinical laboratory services

• Major diagnostics test devices manufacturing companies are emphasizing on developing new products and systems for providing an accurate analysis of samples

• The growing adoption of employer-sponsored wellness programs is expected to fuel the growth of the market.

On the other hand, the rigid regulatory environment is the major factor that is expected to hamper the growth of the global clinical laboratory services market in the next few years.

By geography, the Asia Pacific market for clinical laboratory services is projected to witness high growth in the next few years, due to the growing population in this region coupled with high unmet medical requirements. The healthcare reimbursement situation in Asia Pacific is extremely unorganized, resulting in the curtailed growth of the clinical laboratory services market. In 2012, the North America market for clinical laboratory services dominated the overall market in terms of revenue, and is projected to continue to lead, thanks to the favorable reimbursement set-up, sophisticated healthcare infrastructure, and the growing prevalence of several diseases.

The global market for clinical laboratory services has been highly oligopolistic owing to the few players that dominate the market. The dominant players operating in the global clinical laboratory services market are Genoptix Medical Laboratory, Labco S.A., Healthscope, Spectra Laboratories, Charles River Laboratories, Laboratory Corporation of America Holdings, Abbott Laboratories, Quest Diagnostics, Inc., Sonic Healthcare, and Bio-Reference Laboratories.